RebrAIn recently held the inaugural meeting of its Medical Advisory Board (MAB), marking a significant milestone in the company’s ongoing mission to deliver transformative AI-powered tools to neurosurgeons. The meeting also underscored RebrAIn’s pivotal role in shaping the future of AI-driven neurosurgery.
The board consists of globally renowned experts in neurology and neurosurgery, all focused on guiding the company’s next steps in delivering cutting-edge AI solutions to improve surgical outcomes :
- Ausaf Bari, MD, PhD (University of California Los Angeles)
- Rees Cosgrove, MD (Brigham and Women’s Hospital)
- Lain Hermes González, MD (Clínica Universidad)
- Joohi Jimenez-Shahed, MD (Mount Sinai)
- Michael Kinsman, MD (University of Kansas Hospital)
- Shayan Moosa, MD (University of Virginia)
- Charles Munyon, MD (Charlotte Novant Health)
- Jean Régis, MD (Assistance Publique – Hôpitaux de Marseille)
- John Rolston, MD, PhD (Brigham and Women’s Hospital)
“The formation of this advisory board represents an important step in ensuring that RebrAIn’s innovations are grounded in clinical realities” said Prof. Emmanuel Cuny, co-founder of RebrAIn. “We look forward to working closely with these experts to further refine our solutions and push the boundaries of what’s possible in neurosurgical care.”
The board members shared insights on the clinical applications of RebrAIn’s services discussing how its expanded capabilities—now FDA-cleared for targeting additional brain regions—can best be integrated into clinical practice.
The collaboration between RebrAIn and its Medical Advisory Board will be essential in shaping the future of AI-assisted neurosurgical procedures, bringing more personalized and precise treatments to patients worldwide.
Learn more about RebrAIn’s Scientific Board
